Evidence map›Paper›PMID 41795016›Full record

ArticleScientific reports2026

Junction opener enables CAR T cell treatment of solid tumors.

Steven J Reed, Shibbu Sharma, Carrie Novák, Jiho Kim, Kaman Kim, Erene Niemi, Nicholas Korjeff, André Lieber, Steven G Reed, Malcolm S Duthie and 1 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Scientific reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors.

Steven J ReedHDT Bio, 1150 Eastlake Ave E, Suite 200A, Seattle, WA, 98109, USA.
Shibbu SharmaHDT Bio, 1150 Eastlake Ave E, Suite 200A, Seattle, WA, 98109, USA.
Carrie NovákHDT Bio, 1150 Eastlake Ave E, Suite 200A, Seattle, WA, 98109, USA.
Jiho KimHDT Bio, 1150 Eastlake Ave E, Suite 200A, Seattle, WA, 98109, USA.
Kaman KimXyphos Biosciences, an Astellas Company, 480 Forbes Blvd, South San Francisco, CA, 94080, USA.
Erene NiemiXyphos Biosciences, an Astellas Company, 480 Forbes Blvd, South San Francisco, CA, 94080, USA.
Nicholas KorjeffXyphos Biosciences, an Astellas Company, 480 Forbes Blvd, South San Francisco, CA, 94080, USA.
André LieberDivision of Medical Genetics, School of Medicine, University of Washington, Seattle, WA, 98195, USA.
Steven G ReedHDT Bio, 1150 Eastlake Ave E, Suite 200A, Seattle, WA, 98109, USA.
Malcolm S DuthieHDT Bio, 1150 Eastlake Ave E, Suite 200A, Seattle, WA, 98109, USA.
Darrick CarterHDT Bio, 1150 Eastlake Ave E, Suite 200A, Seattle, WA, 98109, USA. darrick.carter@pailifesciences.com.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Physical barriers presented by solid tumors limit CAR T cell efficacy. Thus, technologies to increase CAR T cell access to solid tumors could have massive implications in advancing CAR T cell therapies. Here we demonstrate that treatment of solid tumor-bearing mice with our Junction Opener technology and CAR T cells enhances tumor control - potentially enabling CAR T cell immunotherapy for solid tumors.

Indexed as

Immunotherapy, AdoptiveNeoplasmsReceptors, Chimeric AntigenT-LymphocytesAnimalsCell Line, TumorHumansMiceTumor MicroenvironmentReceptors, Chimeric AntigenCAR T cellsInfiltrationJunction openerSolid tumorsTumor microenvironment

Identifiers

PMID41795016
PMCPMC13086946

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.